Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cincor Pharma Inc (CINC)

Cincor Pharma Inc (CINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Balance Sheet for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)
  06-2021 03-2021 12-2020
Assets
Current Assets
Cash & Cash Equivalents N/A N/A 26,078
Other current assets 0 0 722
TOTAL $N/A $N/A $26,800
Non-Current Assets
TOTAL $N/A $N/A $N/A
Total Assets $N/A $N/A $26,800
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 0 0 3,765
Accrued Expenses N/A N/A 1,236
Other current liabilities N/A N/A 1,890
TOTAL $N/A $N/A $6,891
Non-Current Liabilities
TOTAL $N/A $N/A $N/A
Total Liabilities $N/A $N/A $6,891
Shareholders' Equity
Retained earnings N/A N/A -27,334
Other shareholders' equity 0 0 47,174
TOTAL $N/A $N/A $19,909
Total Liabilities And Equity $0 $0 $26,800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.